Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5678 in High-Risk, Localized Prostate Cancer Prior to Radical Prostatectomy
NCT06085664Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2023
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of nezastomig in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2023; status: recruiting.
02
Drugs
nezastomig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06085664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085664.